Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma

Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis

(2015) Karen Dybkær et al.   JOURNAL OF CLINICAL ONCOLOGY

Bone marrow18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma

(2014) Hugo J.A. Adams et al.   AMERICAN JOURNAL OF HEMATOLOGY

Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?

(2014) L. A. Guardado Sánchez et al.   ANNALS OF HEMATOLOGY

Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse

(2014) Xin-xin Cao et al.   ANNALS OF HEMATOLOGY

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

(2014) Laurie H. Sehn et al.   BLOOD

A clinician's guide to double hit lymphomas

(2014) Chan Yoon Cheah et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan

(2014) T. Aoki et al.   HAEMATOLOGICA

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas

(2013) Raju K. Pillai et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement

(2013) A. B. Khan et al.   BLOOD

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Does Biopsy

(2013) L. Berthet et al.   JOURNAL OF NUCLEAR MEDICINE

Impact of18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement

(2013) Tarec Christoffer El-Galaly et al.   LEUKEMIA & LYMPHOMA

Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma

(2011) Junshik Hong et al.   ANNALS OF HEMATOLOGY

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

(2011) A. O. Gang et al.   ANNALS OF ONCOLOGY

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone

(2010) David Hui et al.   LEUKEMIA & LYMPHOMA

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma

(2010) Changhoon Yoo et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

(2009) N. Tomita et al.   HAEMATOLOGICA

Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases

(2009) Eyas M Hattab et al.   MODERN PATHOLOGY

Clinical significance of 8q24/c-MYCtranslocation in diffuse large B-cell lymphoma

(2008) Nozomi Niitsu et al.   CANCER SCIENCE

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY